Non-Small-Cell Lung Cancer
Conditions
Keywords
Nonsmall Cell Lung cancer, advanced, Second-line, topotecan, Hycamtin, oral, docetaxel
Brief summary
The purpose of this study is to collect information on how effective and how well tolerated an oral investigational drug is compared to a standard intravenous drug in patients with pretreated, advanced non-small lung cancer (NSCLC).
Interventions
DRUGtopotecan
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Written informed consent * Patients with advanced non-small cell lung cancer (NSCLC). * Patients who have received one previous chemotherapy for NSCLC. * Full recovery from previous chemotherapy. * Presence of either measurable or non-measurable disease by radiologic study or physical examination. * At least 3 weeks since last major surgery (a lesser period is acceptable if deemed in the best interest of the patient). * At least 24 hours since prior radiotherapy providing that marked bone marrow suppression is NOT expected. Patients who have received radiotherapy must have recovered from any reversible side effects (e.g. nausea and vomiting). * Laboratory criteria: Patients must have adequate bone marrow reserve and adequate kidney and liver function.
Exclusion criteria
* Symptoms of brain metastasis (cancer spreading to the brain), requiring treatment with steroids. * Active infection. * Severe medical problems other than the diagnosis of NSCLC, that would limit the ability of the patient to follow study guidelines or expose the patient to extreme risk. * Ongoing or planned chemotherapy, immunotherapy, radiotherapy, or investigational therapy for the treatment of NSCLC. * Use of investigational drug within 30 days prior to the first dose of study medication. * Women who are pregnant or lactating. * Patients of child-bearing potential refusing to practice adequate birth control methods. * Patients with conditions which might alter absorption of an oral drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| One-year survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival, time to progression, response rate, response duration, time to response, improvement in quality of life and patient well-being, and qualitative and quantitative toxicities. | — |
Countries
Australia, Austria, Belgium, Canada, China, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Italy, Latvia, Lithuania, Netherlands, New Zealand, Philippines, Poland, Portugal, Russia, Singapore, South Africa, Spain, Switzerland, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom
Outcome results
None listed